image adapted from https://next.cancer.gov/discoveryResources/cbc.htm, Division of Cancer Treatment and Diagnosis, National Cancer Institute, part of the U.S. National Institutes of Health’
At IRBM, we are aware that a screening campaign’s success is critically dependent on the quality and reproducibility of the assays used. Together with the NIH, academic institutions and pharmaceutical companies, we are participating in an EATRIS consortium initiative to help investigate this issue. This collaboration is the first systematic study by translational scientists into the reproducibility of high-throughput screening (HTS) campaigns.
Learn more here.